You can buy or sell AIMT and other stocks, options, ETFs, and crypto commission-free!
Aimmune Therapeutics, Inc. Common Stock, also called Aimmune Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Read More Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.
52 Week High
52 Week Low
Research And Development
Simply Wall StMar 25
The Aimmune Therapeutics (NASDAQ:AIMT) Share Price Has Gained 63% And Shareholders Are Hoping For More
By buying an index fund, investors can approximate the average market return. But if you pick the right individual stocks, you could make more than that. For example, the Aimmune Therapeutics, Inc. (NASDAQ:AIMT) share price is up 63% in the last three years, clearly besting than the market return of around 38% (not including dividends). View our latest analysis for Aimmune Therapeutics Aimmune Therapeutics didn’t have any revenue in the last year, so it’s fair to say it doesn’t yet have a proven product (...
Associated PressMar 18
U.S. FDA Accepts BLA Filing of Aimmune Therapeutics’ AR101 for Peanut Allergy
BRISBANE, Calif.--(BUSINESS WIRE)--Mar 18, 2019--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that the Biologics License Application (BLA) for AR101 has been accepted for review by the U.S. Food and Drug Administration (FDA). “Today is a significant milestone for Aimmune. The FDA’s acceptance of our BLA is a crucial step forward in delivering AR101 to children, teens and families living with the serious, da...
Stock Price, News, & Analysis for Aimmune Therapeutics
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in...
Expected May 8, After Hours